Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26622325
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Ther+Adv+Musculoskelet+Dis
2015 ; 7
(6
): 234-46
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Key issues in the management of patients with systemic lupus erythematosus:
latest developments and clinical implications
#MMPMID26622325
Jordan N
; D'Cruz D
Ther Adv Musculoskelet Dis
2015[Dec]; 7
(6
): 234-46
PMID26622325
show ga
Systemic lupus erythematous (SLE) is a chronic multisystem disease with
significant associated morbidity and mortality. A deeper understanding of the
pathogenesis of SLE has led to the development of biologic agents, primarily
targeting B cells and others inhibiting costimulatory molecules, type I
interferons and cytokines such as interleukin-6. Several of these agents have
been studied in clinical trials; some have shown promise while others have
yielded disappointing results. Economic and regulatory issues continue to hamper
the availability of such therapies for SLE patients. With increasing recognition
that recurrent flares of disease activity lead to long-term damage accrual, one
of the most important recent developments in patient management has been the
concept of treat-to-target in SLE while minimizing patient exposure to excessive
corticosteroid and other immunosuppressive therapy. This article reviews these
key issues in SLE management, outlining recent developments and clinical
implications for patients.